{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:07:03Z","timestamp":1784365623810,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As immune checkpoint inhibitors (ICI) are increasingly being used due to effectiveness in various tumor entities, rare side effects occur more frequently. Pericardial effusion has been reported in patients with advanced non-small cell lung cancer (NSCLC) after or under treatment with immune checkpoint inhibitors. However, knowledge about serositis and edemas induced by checkpoint inhibitors in other tumor entities is scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>Four cases with sudden onset of checkpoint inhibitor induced serositis (irSerositis) are presented including one patient with metastatic cervical cancer, two with metastatic melanoma and one with non-small cell lung cancer (NSCLC). In all cases treatment with steroids was successful in the beginning, but did not lead to complete recovery of the patients. All patients required multiple punctures. Three of the patients presented with additional peripheral edema; in one patient only the lower extremities were affected, whereas the entire body, even face and eyelids were involved in the other patients. In all patients serositis was accompanied by other immune-related adverse events (irAEs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ICI-induced serositis and effusions are complex to diagnose and treat and might be underdiagnosed. For differentiation from malignant serositis pathology of the punctured fluid can be helpful (lymphocytes vs. malignant cells). Identifying irSerositis as early as possible is essential since steroids can improve symptoms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00262-022-03211-7","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:05:41Z","timestamp":1652699141000},"page":"3087-3092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Checkpoint-inhibitor induced Polyserositis with Edema"],"prefix":"10.1007","volume":"71","author":[{"given":"Sarah","family":"Zierold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Semra","family":"Akcetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marie","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Tomsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rudelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-3643","authenticated-orcid":false,"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"issue":"2","key":"3211_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/CCO.0000000000000358","volume":"29","author":"L Heinzerling","year":"2017","unstructured":"Heinzerling L, Goldinger SM (2017) A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol 29(2):136\u2013144","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"3211_CR2","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jfma.2019.07.025","volume":"119","author":"DY Chen","year":"2020","unstructured":"Chen DY, Huang WK, Wu VCC, Chang WC, Chen JS, Chuang CK et al (2020) Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology. J Formos Med Assoc 119(10):1461\u20131475","journal-title":"J Formos Med Assoc"},{"key":"3211_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50","journal-title":"J Immunother Cancer"},{"issue":"19","key":"3211_CR4","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.3390\/ijms21197195","volume":"21","author":"G S\u0142awi\u0144ski","year":"2020","unstructured":"S\u0142awi\u0144ski G, Wrona A, D\u0105browska-Kugacka A, Raczak G, Lewicka E (2020) Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer: a review. Int J Mol Sci 21(19):7195","journal-title":"Int J Mol Sci"},{"key":"3211_CR5","doi-asserted-by":"publisher","first-page":"663088","DOI":"10.3389\/fphar.2021.663088","volume":"12","author":"Z Ma","year":"2021","unstructured":"Ma Z, Pei J, Sun X, Liu L, Lu W, Guo Q et al (2021) Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol 12:663088","journal-title":"Front Pharmacol"},{"key":"3211_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ijcard.2016.08.023","volume":"222","author":"J Nesfeder","year":"2016","unstructured":"Nesfeder J, Elsensohn AN, Thind M, Lennon J, Domsky S (2016) Pericardial effusion with tamponade physiology induced by nivolumab. Int J Cardiol 222:613\u2013614","journal-title":"Int J Cardiol"},{"issue":"1","key":"3211_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","volume":"7","author":"A Saade","year":"2019","unstructured":"Saade A, Mansuet-Lupo A, Arrondeau J, Thibault C, Mirabel M, Goldwasser F et al (2019) Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer 7(1):266","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3211_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000447053","volume":"136","author":"I Kushnir","year":"2017","unstructured":"Kushnir I, Wolf I (2017) Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology 136(1):49\u201351","journal-title":"Cardiology"},{"key":"3211_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","volume":"4","author":"BC Kolla","year":"2016","unstructured":"Kolla BC, Patel MR (2016) Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. J Immunother Cancer 4:80","journal-title":"J Immunother Cancer"},{"key":"3211_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2021.03.015","volume":"155","author":"N Epaillard","year":"2021","unstructured":"Epaillard N, Benitez JC, Gorria T, Fabre E, Riudavets M, Reyes R et al (2021) Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): the pluie study. Lung Cancer 155:114\u2013119","journal-title":"Lung Cancer"},{"issue":"1","key":"3211_CR11","doi-asserted-by":"publisher","first-page":"9381","DOI":"10.1038\/s41598-021-89043-4","volume":"11","author":"PH Lee","year":"2021","unstructured":"Lee PH, Yang TY, Chen KC, Huang YH, Tseng JS, Hsu KH et al (2021) Higher CD4\/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors. Sci Rep 11(1):9381","journal-title":"Sci Rep"},{"issue":"5","key":"3211_CR12","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/1759-7714.13399","volume":"11","author":"K Harada","year":"2020","unstructured":"Harada K, Ogasawara M, Shido A, Meno A, Oda S, Yoshida S et al (2020) Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: a case report and review of the literature. Thorac Cancer 11(5):1350\u20131353","journal-title":"Thorac Cancer"},{"issue":"2","key":"3211_CR13","first-page":"yty038","volume":"2","author":"G Oristrell","year":"2018","unstructured":"Oristrell G, Ba\u00f1eras J, Ros J, Mu\u00f1oz E (2018) Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report. Eur Heart J Case Rep 2(2):yty038","journal-title":"Eur Heart J Case Rep"},{"issue":"7","key":"3211_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/CJI.0000000000000217","volume":"41","author":"DVP de Almeida","year":"2018","unstructured":"de Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC (2018) Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy. J Immunother 41(7):329\u2013331","journal-title":"J Immunother"},{"key":"3211_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fonc.2019.00004","volume":"9","author":"M Yamasaki","year":"2019","unstructured":"Yamasaki M, Daido W, Saito N, Funaishi K, Okada T, Kawamoto K et al (2019) Pericardial effusion with tamponade in lung cancer patients during treatment with nivolumab: a report of two cases. Front Oncol 9:4","journal-title":"Front Oncol"},{"key":"3211_CR16","first-page":"794842","volume":"2015","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S (2015) Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med 2015:794842","journal-title":"Case Rep Oncol Med"},{"issue":"6","key":"3211_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2217\/imt-2019-0003","volume":"11","author":"M Asai","year":"2019","unstructured":"Asai M, Kato Y, Kawai S, Watanabe K, Yomota M, Okuma Y et al (2019) Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report. Immunotherapy 11(6):467\u2013472","journal-title":"Immunotherapy"},{"issue":"1","key":"3211_CR18","doi-asserted-by":"publisher","first-page":"ytab002","DOI":"10.1093\/ehjcr\/ytab002","volume":"5","author":"S Moriyama","year":"2021","unstructured":"Moriyama S, Fukata M, Tatsumoto R, Kono M (2021) Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report. Eur Heart J Case Rep 5(1):ytab002","journal-title":"Eur Heart J Case Rep"},{"key":"3211_CR19","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.2169\/internalmedicine.7219-21","volume":"60","author":"R Sawada","year":"2021","unstructured":"Sawada R, Matsui Y, Uchino J, Okura N, Morimoto Y, Iwasaku M et al (2021) Late-onset pleural and pericardial effusion as immune-related adverse events after 94 cycles of nivolumab: a case report. Intern Med 60:3585\u20133588","journal-title":"Intern Med"},{"key":"3211_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-018-0104-y","volume":"7","author":"S Shaheen","year":"2018","unstructured":"Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT (2018) Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol 7:11","journal-title":"Exp Hematol Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03211-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03211-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03211-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T22:04:15Z","timestamp":1666562655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03211-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3211"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03211-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All co-authors approved the final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ethics approval for our SERIO registry has been granted (Nr. 2_20 B, 17_16 Bc).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}